Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation to Improve Antibody Drug Conjugate Production and Performance

Sortase 肽技术：酶促位点特异性生物缀合可提高抗体药物缀合物的生产和性能

• 批准号: nhmrc : 1039017
• 负责人: A/Pr Christoph Hagemeyer
• 金额: $ 26.81万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/sortase-peptide-technology-production-performance/111239
• 关键词: Sortase; Peptide; Technology; Enzymatic; Site

Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.

癌症的特征是不受控制的细胞生长，导致邻近组织的侵袭和破坏。这是澳大利亚的主要死因。靶向给药是一种有吸引力的治疗策略，具有降低全身药物浓度和减少副作用的潜力。我们正在开发更有效的抗癌药物。